| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2500691 | Farmacia Hospitalaria | 2006 | 7 Pages |
Abstract
In all, 99.01% of patients had safety problems. Pharmacotherapeutic morbidity from adverse effects was less common than reported in clinical trials of these drugs. Most pharmaceutical actions were preventive in nature. Iaser® methodology allows to identify patients with improvement opportunities regarding hepatitis C treatment and the prevention of pharmacotherapeutic morbidity.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
J.F. Márquez-Peiró, C. Pérez-Peiró, J. Carmena-Carmena, N.V. Jiménez-Torres,